Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and ...

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

Advanced Micro Devices, Inc. (NASDAQ:AMD) stock has reached a 52-week low, dipping to $114.41, as investors navigate a challenging market environment. According to InvestingPro data, the company ...

The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake.

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for ...

The partnership will leverage AMD Instinct accelerators and ROCm software to support Absci’s advanced de novo antibody design models. The deal also includes a $20 million private investment in ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct ...

Advanced Micro Devices Inc. is going head-to-head with bigger rival Nvidia Corp. in artificial intelligence-backed drug discovery with news of a new partnership and investment in startup Absci ...

About AMD For more than 50 years AMD has driven $20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct ...

We recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at where Advanced Micro Devices, Inc. (NASDAQ:AMD) stands against other AI ...

The deal is structured as a private investment in a public equity and includes an equity stake in Absci. AMD didn’t disclose the amount of its stake. AMD, which is based in Santa Clara ...